Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...

On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...